Inflammatory Response in Parkinsonism

Journal of Neural Transmission, Supplementa

Volumn , Issue 73, 2009, Pages 245-252

  Barcia, Carlos ^a   Ros, Francisco ^a   Carrillo, María Angeles ^a   Aguado Llera, David ^a   Ros, Carmen María ^a   Gómez, Aurora ^a   Nombela, Cristina ^a   De Pablos, Vicente ^a   Fernández Villalba, Emiliano ^a   Herrero, Maria Trinidad ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Anti inflammatory drugs; Astroglia; Dopaminergic degeneration; Microglia; Neuroinflammation; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CORTICOTROPIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEXAMETHASONE; ESTRADIOL; GAMMA INTERFERON; HYDROCORTISONE; IBUPROFEN; INTERLEUKIN 1; PROGESTERONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; CYTOKINE; GLUCOCORTICOID;

APOPTOSIS; ASTROCYTE; DOPAMINERGIC NERVE CELL; GLIA CELL; HUMAN; INFLAMMATION; LYMPHOCYTE; MACROGLIA; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; ANIMAL; DISEASE MODEL; GLIA; HISTORY; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFLAMMATION; NEUROGLIA; PARKINSONIAN DISORDERS;

EID: 77952294948     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-92660-4_19     Document Type: Review

References (78)

1. Aubin N, Curet O, Deffois A, Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71:1635-1642
2. Bains M, Cousins JC, Roberts JL (2007) Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp Neurol 204:767-776
3. Barcia C, Fernandez Barreiro A, Poza M, Herrero MT (2003a) Parkinson's disease and inflammatory changes. Neurotox Res 5:411-418
4. Barcia C, Bautista V, Sanchez-Bahillo A, Fernandez-Villalba E, Navarro-Ruis JM, Barreiro AF, Poza YPM, Herrero MT (2003b) Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys. Neuroendocrinology 78:118-128
5. Barcia C, Emborg ME, Hirsch EC, Herrero MT (2004a) Blood vessels and Parkinsonism. Front Biosci 9:277-282
6. Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza YPM, Fernandez-Barreiro A, Hirsch EC, Herrero MT (2004b) Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46:402-409
7. Barcia C, de Pablos V, Bautista-Hernandez V, Sanchez-Bahillo A, Bernal I, Fernandez-Villalba E, Martin J, Banon R, Fernandez-Barreiro A, Herrero MT (2005a) Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration. Parkinsonism Relat Disord 11:435-439
8. Barcia C, Bautista V, Sanchez-Bahillo A, Fernandez-Villalba E, Faucheux B, Poza y Poza M, Fernandez Barreiro A, Hirsch EC, Herrero MT (2005b) Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm 112:1237-1248
9. Benveniste EN, Kwon J, Chung WJ, Sampson J, Pandya K, Tang LP (1994) Differential modulation of astrocyte cytokine gene expression by TGF-beta. J Immunol 153:5210-5221
10. Bialecka M, Klodowska-Duda G, Kurzawski M, Slawek J, Gorzkowska A, Opala G, Bialecki P, Sagan L, Drozdzik M (2008) Interleukin-10 (IL10) and tumor necrosis factor alpha (TNF) gene polymorphisms in Parkinson's disease patients. Parkinsonism Relat Disord 14:636-640
11. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202:17-20
12. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 172:151-154
13. Bornebroek M, deLau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH, Breteler MM (2007) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 28:193-196
14. Bower JH, Maraganore DM, Peterson BJ, Ahlskog JE, Rocca WA (2006) Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 67:494-496
15. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182-192
16. Callier S, Morissette M, Grandbois M, Pelaprat D, Di Paolo T (2001) Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 41:131-138
17. Carrasco E, Casper D, Werner P (2005) Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity. J Neurosci Res 81:121-131
18. Casper D, Yaparpalvi U, Rempel N, Werner P (2000) Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 289:201-204
19. Chae SW, Kang BY, Hwang O, Choi HJ (2008) Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells. Neurosci Lett 436:205-209
20. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A (2003) Nonsteroidal antiinflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059-1064
21. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58:963-967
22. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A (2008) Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 167:90-95
23. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5:137-143
24. de Pablos V, Barcia C, Martinez S, Soria JM, Rodriguez JM, Ceron JJ, Herrero MT (2004) Serum C Reactive Protein (CRP) levels in Parkinsonian monkeys treated with trifusal. Society for Neuroscience, San Diego, CA
25. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C (1993) Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7:75-83
26. Dluzen DE, McDermott JL, Liu B (1996) Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 18:603-606
27. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G (2007) Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 205:295-312
28. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC (1999) Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353:981-982
29. Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R, Hong JS (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridineinduced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329:354-358
30. Feng Z, Li D, Fung PC, Pei Z, Ramsden DB, Ho SL (2003) COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport 14:1927-1929
31. Ferrario JE, Delfino MA, Stefano AV, Zbarsky V, Douhou A, Murer MG, Raisman-Vozari R, Gershanik OS (2003) Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neurosci Res 47:431-436
32. Forno LS, De Lanney LE, Irwin I, Di Monte D, Langston JW (1992) Astrocytes and Parkinson's disease. Prog Brain Res 94:429-436
33. Hakansson A, Westberg L, Nilsson S, Buervenich S, Carmine A, Holmberg B, Sydow O, Olson L, Johnels B, Eriksson E, Nissbrandt H (2005) Investigation of genes coding for inflammatory components in Parkinson's disease. Mov Disord 20:569-573
34. Hakansson A, Bergman O, Chrapkowska C, Westberg L, Belin AC, Sydow O, Johnels B, Olson L, Holmberg B, Nissbrandt H (2007) Cyclooxygenase-2 polymorphisms in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 144:367-369
35. Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK (2007) Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 64:576-580
36. Hanisch UK (2002) Microglia as a source and target of cytokines. Glia 40:140-155
37. Hineno T, Mizobuchi M, Hiratani K, Inami Y, Kakimoto Y (1992) Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in dogs. Brain Res 580:92-99
38. Hirohata M, Ono K, Morinaga A, Yamada M (2008) Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibrildestabilizing effects for alpha-synuclein fibrils in vitro. Neuropharmacology 54:620-627
39. Hirsch EC, Hunot S, Damier P, Faucheux B (1998) Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol: S115-S120
40. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 991:214-228
41. Jankovic J, Kapadia AS (2001) Functional decline in Parkinson disease. Arch Neurol 58:1611-1615
42. Kanaan NM, Kordower JH, Collier TJ (2008) Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure in monkeys. Glia 56:1199-214.
43. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ (2007) Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain 130:2123-2128
44. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A (1999) The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156:50-61
45. Kurkowska-Jastrzebska I, Litwin T, Joniec I, Ciesielska A, Przybylkowski A, Czlonkowski A, Czlonkowska A (2004) Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int Immunopharmacol 4:1307-1318
46. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980
47. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure. Ann Neurol 46:598-605
48. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG (2006) Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 26:9365-9375
49. McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10 Suppl: S3-S7
50. McGeer EG, McGeer PL (2007) The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs 21:789-797
51. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291
52. McGeer PL, Schwab C, Parent A, Doudet D (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration. Ann Neurol 54:599-604
53. Merrill JE, Benveniste EN (1996) Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci 19:331-338
54. Mizobuchi M, Hineno T, Kakimoto Y, Hiratani K (1993) Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated dogs. Brain Res 612:319-321
55. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994a) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165:208-210
56. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994b) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147-150
57. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile Parkinsonism and Parkinson's disease. Neurosci Lett 211:13-16
58. Morale MC, Serra PA, Delogu MR, Migheli R, Rocchitta G, Tirolo C, Caniglia S, Testa N, L'Episcopo F, Gennuso F, Scoto GM, Barden N, Miele E, Desole MS, Marchetti B (2004) Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. Faseb J 18:164-166
59. Morale MC, Serra PA, L'Episcopo F, Tirolo C, Caniglia S, Testa N, Gennuso F, Giaquinta G, Rocchitta G, Desole MS, Miele E, Marchetti B (2006) Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 138:869-878
60. Morissette M, Jourdain S, Al Sweidi S, Menniti FS, Ramirez AD, Di Paolo T (2007) Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity. Neuropharmacology 52:1509-1520
61. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS (2007) Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 27:3328-3337
62. Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, Raisman-Vozari R (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43:561-575
63. Nagatsu T, Sawada M (2007) Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl 72:113-120
64. Rabey JM, Scharf M, Oberman Z, Zohar M, Graff E (1990) Cortisol, ACTH, and beta-endorphin after dexamethasone administration in Parkinson's dementia. Biol Psychiatry 27:581-591
65. Ramirez AD, Liu X, Menniti FS (2003) Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 77:223-231
66. Sánchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O (2004) Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 1:6
67. Schiess M (2003) Nonsteroidal anti-inflammatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away? Arch Neurol 60:1043-1044
68. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP (2002) Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. Faseb J 16:1474-1476
69. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP (2006) Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. Faseb J 20:670-682
70. Stypula G, Kunert-Radek J, Stepien H, Zylinska K, Pawlikowski M (1996) Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease. Neuroimmunomodulation 3:131-134
71. Tansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208:1-25
72. Tedeschi B, Barrett JN, Keane RW (1986) Astrocytes produce interferon that enhances the expression of H-2 antigens on a subpopulation of brain cells. J Cell Biol 102:2244-2253
73. Teismann P, Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39:167-174
74. Teismann P, Vila M, Choi DK, Tieu K, Wu DC, Jackson-Lewis V, Przedborski S (2003) COX-2 and neurodegeneration in Parkinson's disease. Ann N Y Acad Sci 991:272-277
75. Ton TG, Heckbert SR, Longstreth WT Jr, Rossing MA, Kukull WA, Franklin GM, Swanson PD, Smith-Weller T, Checkoway H (2006) Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 21:964-969
76. Tripanichkul W, Sripanichkulchai K, Finkelstein DI (2006) Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication. Brain Res 1084:28-37
77. Wahner AD, Bronstein JM, Bordelon YM, Ritz B (2007) Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69:1836-1842
78. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J (2004) Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 75:637-639